Prucalopride, a dihydrobenzofuran formamide compound and highly selective 5-HT4 receptor agonist, was reported by Chen et al. to inhibit the proliferation, invasion, and migration of lung cancer cells by blocking the PI3K/Akt/mTOR signaling pathway (Chen M. et al., 2019). The gene discussed is AKT1; the disease is lung cancer.